Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma - Top-Institutions - MDSpire

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

  • By

  • Meletios A. Dimopoulos

  • Sagar Lonial

  • Wee-Joo Chng

  • Shinsuke Iida

  • María-Victoria Mateos

  • Gareth J. Morgan

  • Cong Li

  • Catriona Byrne

  • Kaveri Suryanarayan

  • Richard Labotka

  • S. Vincent Rajkumar

  • December 4, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #4

    University of Arkansas for Medical Sciences
    University of Arkansas for Medical Sciences

    Little Rock, AR

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

Original Source(s)

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

  • by Meletios A. Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos, Gareth J. Morgan, Cong Li, Catriona Byrne, Kaveri Suryanarayan, Richard Labotka, S. Vincent Rajkumar

  • December 4, 2025

Related Content

Clinical Reasoning in Practice: Implementing High-Value Care When Data Discrepancies Arise

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series